|
|
Article: Phase III Trial of Avastin Plus Chemotherapy Markedly Extends Survival of Metastatic Colorectal Cancer Patients.
- Article from:
- Business Wire
- Article date:
- May 19, 2003
CopyrightCOPYRIGHT 2003 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Business Editors/Health/Medical Writers
BIOWIRE2K
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--May 19, 2003
First Positive Phase III Results With an Anti-Angiogenic Therapy
for Cancer; Data to be Submitted to Upcoming ASCO Meeting
Genentech, Inc. (NYSE:DNA) today announced that a Phase III study of Avastin(TM) (bevacizumab, rhuMAb-VEGF) plus chemotherapy in previously-untreated metastatic colorectal cancer patients met its primary endpoint of improving overall survival. The magnitude of the benefit observed far exceeded what the study was designed to demonstrate. The trial also met the secondary endpoints of progression-free ...